Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

Fig. 8

Effects of EGF, cetuximab, trastuzumab and afatinib treatment on caspase 3 activation. MKN1 and Hs746T cells were treated with EGF, EGF + cetuximab (EGF + Cet), cetuximab (Cet), trastuzumab (Tra), afatinib (Afa) or trastuzumab + afatinib (Tra + Afa) for 24 h. MKN7 and NCI-N87 were treated with trastuzumab (Tra), afatinib (Afa) or trastuzumab + afatinib (Tra + Afa) for 24 h. Cell lysates were analyzed by western blot with antibodies against cleaved (cl.) caspase 3 (Asp175). The mean of three biological experiments with standard deviation is shown. Significant effects compared to untreated are indicated by *p < 0.05 (one-sample t-test). Full-length blots are presented in Additional file 5

Back to article page
\